SIMCERE PHARMAC. GRP LTD
Research SIMCERE PHARMAC. GRP LTD (S2P) on Bullrun: market cap EUR 2.67B, P/E 14.9, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerS2P
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 2.67B
- P/E14.9
- Dividend yield2.3%
- Financial periodFY2024
- RevenueEUR 6.64B
- Revenue growth0.4%
- Net incomeEUR 733.17M
- Free cash flowEUR 628.54M
- Gross margin80.2%
Valuation Snapshot
latest market cap is EUR 2.67B; P/E is 14.9; dividend yield is 2.3%.
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor;
Frequently asked questions
What is SIMCERE PHARMAC. GRP LTD's market cap?
SIMCERE PHARMAC. GRP LTD's market capitalization is EUR 2.67B.
What is SIMCERE PHARMAC. GRP LTD's P/E ratio?
SIMCERE PHARMAC. GRP LTD's price-to-earnings (P/E) ratio is 14.9.
Does SIMCERE PHARMAC. GRP LTD pay a dividend?
SIMCERE PHARMAC. GRP LTD has a dividend yield of 2.3%.
What does SIMCERE PHARMAC. GRP LTD do?
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.